Search

Your search keyword '"Freire-Gonzalez M"' showing total 4 results
Start Over Author "Freire-Gonzalez M" Language undetermined
4 results on '"Freire-Gonzalez M"'

1. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

Author

Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Rubio J, Ortego N, Fernandez-Diaz C, Rubio E, Garcia-Morillo S, Minguez M, Fernandez-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz-Sanjuan F, de Pedro I, Alonso-Valdivielso J, Perez-Sanchez L, Roldan R, Fernandez-Llanio N, de la Torre R, Suarez S, Cabrera M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R

Subjects
Takayasu's arteritis, cDMARDs, biological therapy, Caucasian, Tocilizumab
Abstract

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

Published
2021

2. FACTORS AFFECTING MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SPAIN IN THE 21ST CENTURY: DATA FROM THE RELESSER REGISTRY

Author

Moriano C, Calvo-Alen J, Rua-Figueroa I, Alvarez E, Bermudez C, Lopez-Longo F, Galindo-Izquierdo M, Olive-Marques A, Muriel E, Fernandez-Nebro A, Freire-Gonzalez M, Fernandez-Berrizbeitia O, Gomez A, Uriarte M, Fernandez-Cid C, Morales C, Soler G, Blanco R, Rodriguez-Gomez M, Vela P, Boteanu A, Narvaez F, Taboada V, Cruz B, Sanchez J, Hernandez-Beriain J, Exposito L, Almagro R, Ibanez-Barcelo M, Castellvi I, Galisteo C, Raya E, Quevedo-Vila V, Vazquez T, Ibanez-Ruan J, and Pego-Reigosa J

Published
2020

3. Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?

Author

Segura B, Gonzalez I, Rua-Figueroa I, Veiga N, Perez V, Olive-Marques A, Galindo-Izquierdo M, Calvo-Alen J, Ovalles-Bonilla J, Fernandez-Nebro A, Almagro R, Muriel E, Del-val-del-amo N, Uriarte M, Taboada V, Sanchez J, Boteanu A, Narvaez F, Morasat A, Morales C, Gallego J, Cruz B, Andres M, Perez E, Freire-Gonzalez M, Garcia S, Moriano C, Exposito L, Perez-Velasquez C, Velloso-Feijoo M, Cacheda A, Rivas N, Bonilla G, Arevalo M, Jimenez I, Quevedo-Vila V, Manero-Ruiz F, de la Pena P, Vazquez-Rodriguez T, Ibanez-Ruan J, Cobo-Ibanez T, and Pego-Reigosa J

Published
2020

4. Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis

Author

González-Álvaro, I., Castrejón, I., Ortiz, A.M., Toledano, E., Castañeda, S., García-Vadillo, A., Carmona, L., Abasolo Alcazar, L., Miguel, Alegre De, Andreu Sánchez, J.L., Aragón Díez, A., Balsa Criado, A., Batlle Gualda, E., Belmonte Serrano, M.A., Beltrán Audera, J., Beltrán Fabregat, J., Bonilla Hernan, G., Carmona Ortells, L., Caro Fernández, N., Casado, E., Cebrian Mendez, L., Corteguera Coro, M., Cuadra Díaz, J.L., Cuesta, E., Fiter Aresté, J., Freire Gonzalez, M., Galindo Izquierdo, M., García Meijide, J.A., García Gómez, M.C., Giménez Ubeda, E., Gómez Centeno, E., Gómez Vaquero, C., González Fernández, M.J., González Gómez, M.L., González Hernández, T., González-Alvaro, I., González-Montagut Gómez, C., Grandal Delgado, Y., Gratacos Masmitja, J., Hernández, Del R., Instxaurbe, A.R., Irigoyen Oyarzabal, M.V., Jiménez Palop, M., Juan Mas, A., Júdez Navarro, E., Larrosa Padro, M., López Longo, F.J., Loza Santamaria, E., Maese Manzano, J., Manero Ruiz, F.J., Mateo Bernardo, I., Mayordomo González, L., Mazzucheli, R., Medrano, San Idelfonso, Naranjo Hernández, A., Pecondón Español, A., Peiró Callizo, E., Quirós Donate, J., Ramos López, P., Rivera Redondo, J., Rodríguez Gómez, M., Rodríguez López, M., Roselló Pardo, R., Sampedro Alvarez, J., Sanmartí Sala, R., Santos, Rey Rey, Tena Marsá, X., Tenorio Martín, M., Torres Martín, Mc, Ureña Garnica, I., Diego, Valdazo De, Valls, M., Villaverde García, V., Zarco Montejo, P., and Zubieta Tabernero, J.

Abstract

Objective To estimate cut-off points and to establish response criteria for the Hospital Universitario La Princesa Index (HUPI) in patients with chronic polyarthritis. Methods Two cohorts, one of early arthritis (Princesa Early Arthritis Register Longitudinal PEARL] study) and other of long-term rheumatoid arthritis (Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide EMECAR]) including altogether 1200 patients were used to determine cut-off values for remission, and for low, moderate and high activity through receiver operating curve (ROC) analysis. The areas under ROC (AUC) were compared to those of validated indexes (SDAI, CDAI, DAS28). ROC analysis was also applied to establish minimal and relevant clinical improvement for HUPI. Results The best cut-off points for HUPI are 2, 5 and 9, classifying RA activity as remission if =2, low disease activity if >2 and =5), moderate if >5 and

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results